Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aptamer Group Plc (GB:APTA)
LSE:APTA
Aptamer Group Plc (APTA) Share Price & Analysis
2 Followers
APTA Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range0.45p - 30.50p
Previous Close0.68p
Volume4.46M
Average Volume (3M)7.31M
Market Cap
£3.15M
Enterprise Value5.69M
Total Cash (Recent Filing)£702.00K
Total Debt (Recent Filing)£3.23M
Price to Earnings (P/E)>-0.1
Beta1.66
Next Earnings
Oct 15, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume7,310,451
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aptamer Group Plc News
PremiumCompany Announcements
Aptamer Group Advances in Life Sciences Innovation
PremiumCompany Announcements
Aptamer Group Shareholder Voting Power Shifts
PremiumCompany Announcements
Aptamer Group Sees Shift in Major Holdings
PremiumCompany Announcements
Aptamer Group Announces Major Share Ownership ChangePremiumCompany Announcements
Aptamer Group Shareholder Voting Rights Shift
PremiumCompany Announcements
Aptamer Group’s Optimer Poised to Revolutionize Liver Disease Treatment
PremiumCompany Announcements
Aptamer Group Plc Announces Major Shareholder Change
PremiumCompany Announcements
Aptamer Group Advances Transplant Therapy InnovationOptions Prices
Currently, No data available
---
Ownership Overview
13.27% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
86.73% Public Companies and
Individual Investors
APTA FAQ
What was Aptamer Group Plc’s price range in the past 12 months?
Aptamer Group Plc lowest share price was 0.45p and its highest was 30.50p in the past 12 months.
What is Aptamer Group Plc’s market cap?
Currently, no data Available
When is Aptamer Group Plc’s upcoming earnings report date?
Aptamer Group Plc’s upcoming earnings report date is Oct 15, 2024 which is in 147 days.
How were Aptamer Group Plc’s earnings last quarter?
Aptamer Group Plc released its earnings results on Mar 28, 2024. The company reported 0.005p earnings per share for the quarter, beating the consensus estimate of N/A by 0.005p.
Is Aptamer Group Plc overvalued?
According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued.
Does Aptamer Group Plc pay dividends?
Aptamer Group Plc does not currently pay dividends.
What is Aptamer Group Plc’s EPS estimate?
Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptamer Group Plc have?
Aptamer Group Plc has 467,343,660 shares outstanding.
What happened to Aptamer Group Plc’s price movement after its last earnings report?
Aptamer Group Plc reported an EPS of 0.005p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Aptamer Group Plc?
Currently, no hedge funds are holding shares in GB:APTA
---
Aptamer Group Plc Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.57%
12-Months-Change
Fundamentals
Return on Equity
-187.54%
Trailing 12-Months
Asset Growth
-53.81%
Trailing 12-Months
Company Description
Aptamer Group Plc
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.
---
Technical Analysis
---